MedTrace Logo

Study of the Relationship Between rHuEPO Dose, Serum ADPN, and Mortality in Patients Beginning HD

NCT00457535 · Status: TERMINATED · Type: OBSERVATIONAL

Last updated 2007-04-06

No results posted yet for this study

Summary

Responsiveness of recombinant human erythropoietin (rHuEPO) is known to be related with body fatness in hemodialysis (HD) patients. Adiponectin (ADPN) is inversely associated with body fat mass, and in healthy subjects, low ADPN is a predictor of mortality. Recently, higher rHuEPO dose itself is demonstrated to be associated with poor prognosis. So, in this study, we prospectively examined the relationship between rHuEPO dose, serum ADPN, and mortality in patients beginning HD.

Conditions

  • Renal Dialysis

Sponsors & Collaborators

  • Shitoro Clinic

    collaborator UNKNOWN

  • Fujinomiya City Hospital

    collaborator OTHER

  • Iwata City Hospital

    collaborator OTHER

  • Seirei Mikatabara General Hospital

    collaborator UNKNOWN

  • Seirei Hamamatsu General Hospital

    collaborator OTHER

  • Hamana Clinic

    collaborator OTHER

  • Tadokoro Clinic

    collaborator UNKNOWN

  • Makoto Clinic

    collaborator UNKNOWN

  • Maruyama Memorial General Hospital

    collaborator OTHER

  • Sun-Sanaru Clinic

    collaborator UNKNOWN

  • Hamamatsu University

    lead OTHER

Principal Investigators

  • Naro Ohashi, MD,PhD · First Department of Medicine, Hamamatsu University School of Medicine

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-08-31
Completion
2004-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00457535 on ClinicalTrials.gov